1Saphner T, Tormey D C, Gray R. et al. Annual hazard rates of recurrence for breast cancer after primary therapy [ J ]. J Clin Oneol, 1996, 14: 2738.
2Mouridsen H, Gershanovieh M, Sun Y, et al, Superior efficacy of Letrozole (Femara) versus Tamoxifen as firstline therapy for postmenopausal women with advanced breast cancer: resuits of a phase Ⅲ study of the international Letrozole Breast Cancer Group[J]. J Clin Oneol, 2001, 19(10):2596.
3Goss P E, Ingle J N, Martlno S D O, et al. A Randomized Trial of Letrczole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer[J]. N Engl J Med, 2003, 349: 19.
1Tremblay A, Tremblay G B, Labile F, et al. Ligand- independent recruitment of SRC1 to estrogen receptor beta through phosphorylation of activation function A F- 1 [ J ].Mol Cell, 2001, 3: 513.
2Gee J M, Robertson J F, Ellis I O, et al. Phosphorylation of ERK 1/2 mitogen-aetivated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer[J]. Int J Cancer, 2001, 95(4) : 247.
3Kuiper G G, Enmark, E, Pelto-Huikko, et al. Cloning of a novel receptor expressed in rat prostate and ovary[J]. Proe Nail Acad Sci USA, 1996, 93: 5925.
4Mosselman S, Polman J, Dijkema, R. ER: identification and characterization of a novel human estrogen receptor[J ].FEBS Lett, 1996, 392: 49.
5Tremblay, G B, Tremblay, A, Copeland, N G, et al.Cloning, chromosomal localization, and finctional analysis of the murine estrogen receptor[J ]. Mol Endoerinol, 1997,11 : 353.
6Gazet J C, Coombes R C, Ford H T, et al. Assesssment of the effect of pretreatment with neoadjuvant therapy on primary breast cancer[J]. Br J Cancer, 1996, 73: 758.
7Dixon J M, Love CDB, Tucker S, et al. Letrozole as primary mediesl therapy for locally advanced and large operable breast cancer[J]. Proc ASCO. 1998. 17: 104.
8Jonat W, kaufmann M, Blarney R W, et al. A randomized study to compare the effect of LHRH analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer[J]. Eur J Cancer, 1995, 31A: 137.
9Klijn J G M, Seynaeve C, Beex L, et al. Combined treatment with buserdin (LHRHa) and tamoxifen vs single treatment with each drug alone in premenopausal metastatic breast cancer: preliminary results of EORTC Study 10881 [J]. Proc Am Soe Clin Oncol, 1996, 15: 117.
10Jakesz R, Hausmaninger H, Samonigg H, et al. Comparison of Adjuvant Therapy with Tamoxifen and Goserelin Vs.CMF in Premenopausal SrageI and Ⅱ Hormone-Responsive Breast Cancer Patient.s: Four-Years Results of Austrian Breast Cancer Study Group (ABCSG) Trial 5[C]. 1999,18: 67.
1Ellis M J, Ma C. Letroa)le in the neoadjuvant setting: theF024 trial [J]. Breast Cancer Res Treat, 2007, 105 ( Suppl 1) : 33.
2Holmes C E, Huang J C, Pace T R, et al. Tamoxifen and aromatase inhibitors differentially affect vascular endothelial growth factor and endostatin levels in women with breasl can- cer[J]. Clin Cancer Res, 2008, 14(10) : 3070.
3Maya Dadiani, Dalia Seger, Tamar Kreizman, et al. Estro- gen regulation of vascular endothelial growth factor in breast cancer in vitro and in vivo: the role of estrogen receptor a and c-Mye[J]. Endocr Relat Cancer, 2009, 16(3): 819.
4Rebecca A, Stein, Stephanie Gaillard, et al. Estrogen - re- lated receptor alpha induces the expression of vascular en- dothelial growth factor in breast cancer ceils[J ].JSteroid Biechem Moi Bid, 2(109, 114(1 - 2) : 106.
5Sasaki T, Tanno S, Shibukawa K, et al. Administration of VEGF receptor tyrosine kinase inhibitor increases VEGF pro- duction causing angiogenesis in human small - cell lung cancer xenografts[J]. IntJ Oneol, 2008, 33(3): 525.
